Literature DB >> 11356967

Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

A L Hammond1, J Lewis, J May, J Albert, P Balfe, J A McKeating.   

Abstract

To assess the antigenicity of envelope glycoproteins derived from primary human immunodeficiency virus type 1 populations, their interactions with the receptor CD4, and their coreceptor usage, we have cloned and expressed multiple gp120 proteins from a number of primary virus isolates. Characterization of these proteins showed a high degree of antigenic polymorphism both within the CD4 binding site and in defined neutralization epitopes, which may partially account for the general resistance of primary isolates to neutralizing agents. Furthermore, chimeric viruses expressing gp120 proteins with reduced CD4 binding abilities are viable, suggesting that primary viruses may require a less avid interaction with the receptor CD4 to initiate infection than do their laboratory-adapted counterparts. The coreceptor usage of chimeric viruses was related to the ability of the virus to bind CD4, with reduced CD4 binding correlating with preferential usage of CXCR4. Changes in coreceptor usage mapped to sequence changes in the C2 and V4 regions, with no changes seen in the V3 region.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356967      PMCID: PMC114272          DOI: 10.1128/JVI.75.12.5593-5603.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.

Authors:  J A McKeating; J Bennett; S Zolla-Pazner; M Schutten; S Ashelford; A L Brown; P Balfe
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

2.  Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1.

Authors:  T C VanCott; F R Bethke; V R Polonis; M K Gorny; S Zolla-Pazner; R R Redfield; D L Birx
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

3.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.

Authors:  J Rucker; A L Edinger; M Sharron; M Samson; B Lee; J F Berson; Y Yi; B Margulies; R G Collman; B J Doranz; M Parmentier; R W Doms
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

Authors:  J A McKeating; C Shotton; J Cordell; S Graham; P Balfe; N Sullivan; M Charles; M Page; A Bolmstedt; S Olofsson
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site.

Authors:  J A McKeating; J P Moore; M Ferguson; H S Marsden; S Graham; J W Almond; D J Evans; R A Weiss
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

6.  AIDS-free survival and overall survival in HIV infection: the new CDC classification system (1993) for HIV disease and AIDS.

Authors:  B S Kamps; H R Brodt; S Staszewski; L Bergmann; E B Helm
Journal:  Clin Investig       Date:  1994-03

7.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.

Authors:  S Laal; S Burda; M K Gorny; S Karwowska; A Buchbinder; S Zolla-Pazner
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.

Authors:  D Kabat; S L Kozak; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection.

Authors:  A Karlsson; K Parsmyr; E Sandström; E M Fenyö; J Albert
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

View more
  3 in total

1.  Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.

Authors:  Alexey A Nabatov; Georgios Pollakis; Thomas Linnemann; Aletta Kliphius; Moustapha I M Chalaby; William A Paxton
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.

Authors:  Gustavo H Kijak; Viviana Simon; Peter Balfe; Jeroen Vanderhoeven; Sandra E Pampuro; Carlos Zala; Claudia Ochoa; Pedro Cahn; Martin Markowitz; Horacio Salomon
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

3.  Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner.

Authors:  J A McKeating; L Q Zhang; C Logvinoff; M Flint; J Zhang; J Yu; D Butera; D D Ho; L B Dustin; C M Rice; P Balfe
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.